De Marchis GM, et al. - In this investigation, researchers derived a copeptin-based parsimonious score (with external validation) to forecast detrimental results 3 months following an acute ischemic stroke (AIS). Components of the score were copeptin levels, age, NIH Stroke Scale, and recanalization therapy (CoRisk score). Within 24 hours of AIS and before any recanalization therapy, copeptin levels were measured in plasma. In total, 1,102 patients were included; 319 patients were in the derivation cohort, and 783 were in the validation cohort. Data revealed that the net reclassification index was 46% between the calibrated CoRisk scores with and without copeptin. According to findings, they externally validated the biomarker-based CoRisk score, which was calibrated well, and offered superior performance vs the same score without copeptin for forecasting disability and death.